EUVIMEDSkopri EUVIMED
Open access · CC BY-NC-ND 4.0

Repurposing Hetrombopag for Multiple Myeloma by Targeting PNPO: A Celastrol‐Inspired Approach

Tianyi Yu, Cheng Wang, Jingru Xie, Yongxin Wei, Hongwei Cui, Huaxia Zhang, Fan Zhou, Zhendong Deng, Ye Yang, Chunyan Gu iD

Basic & Clinical Pharmacology & Toxicology · 2026-05 · 138 (5)

DOI: 10.1111/bcpt.70227 ↗

At a glance

Journal article in Basic & Clinical Pharmacology & Toxicology, published online on 2026-03-31. Written by Tianyi Yu and 9 co-authors. Institution: Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China. Major MEDLINE topics: Multiple Myeloma, Triterpenes, Antineoplastic Agents. 71 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: National Natural Science Foundation of China, Priority Academic Program Development of Jiangsu Higher Education Institutions.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Multiple myeloma (MM) is a malignancy of plasma cells whose excessive immunoglobulin production elevates reactive oxygen species (ROS), promoting pathogenesis. Active compounds from Traditional Chinese Medicine, such as celastrol, can exert antitumour effects by further increasing ROS levels to toxic levels, thereby inducing apoptosis. Our previous study has demonstrated that pyridoxine‐5′‐phosphate oxidase (PNPO) is the specific target of celastrol. In this study, we discovered that PNPO, a key enzyme involved in vitamin B6 coenzyme metabolism, is highly expressed in various cancers, including MM. Increased PNPO levels correlated with MM disease progression, promoting cell proliferation and inducing osteoclast differentiation via exosomes. Concurrently, through a structure‐based virtual screening workflow targeting critical PNPO residues (R95 and K117), we identified Hetrombopag as a potential PNPO inhibitor. Hetrombopag simultaneously inhibited MM cell proliferation and osteoclast differentiation. Preliminary data from clinical trials also supported the idea that hetrombopag treatment can prolong survival in MM patients. Our research highlights the significant role of PNPO in MM progression and suggests hetrombopag as a promising therapeutic option for MM treatment.

Subjects

MeSH terms (MEDLINE)

Multiple MyelomaTriterpenesAntineoplastic AgentsHumansCell ProliferationReactive Oxygen SpeciesCell DifferentiationPentacyclic TriterpenesDrug RepositioningOsteoclastsCell Line, TumorAnimals

Author keywords

hetrombopagmultiple myelomaoxidationpyridoxine‐5′‐phosphate oxidasereactive oxygen species

Substances

celastrolReactive Oxygen SpeciesPentacyclic TriterpenesTriterpenesAntineoplastic Agents

Authors and institutions

  • Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
  • School of Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
  • School of Elderly Care Services and Management, Nanjing University of Chinese Medicine, Nanjing, China.
  • Department of Hematology and Oncology, Jing'an District Zhabei Central Hospital, Shanghai, China.

ORCID profiles: Chunyan Gu

Funding

  • National Natural Science Foundation of China
  • Priority Academic Program Development of Jiangsu Higher Education Institutions

Cite

APA

Yu, T., Wang, C., Xie, J., Wei, Y., Cui, H., Zhang, H., Zhou, F., Deng, Z., Yang, Y., & Gu, C. (2026). Repurposing Hetrombopag for Multiple Myeloma by Targeting PNPO: A Celastrol‐Inspired Approach. Basic & Clinical Pharmacology & Toxicology, 138(5). https://doi.org/10.1111/bcpt.70227

Vancouver

Yu T, Wang C, Xie J, Wei Y, Cui H, Zhang H, et al. Repurposing Hetrombopag for Multiple Myeloma by Targeting PNPO: A Celastrol‐Inspired Approach. Basic & Clinical Pharmacology & Toxicology. 2026;138(5). doi:10.1111/bcpt.70227

BibTeX
@article{Yu2026,
  author = {Yu, Tianyi and Wang, Cheng and Xie, Jingru and Wei, Yongxin and Cui, Hongwei and Zhang, Huaxia and Zhou, Fan and Deng, Zhendong and Yang, Ye and Gu, Chunyan},
  title = {Repurposing Hetrombopag for Multiple Myeloma by Targeting PNPO: A Celastrol‐Inspired Approach},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2026},
  volume = {138},
  number = {5},
  doi = {10.1111/bcpt.70227}
}
Start for free →